-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Sunday, Sutro Biopharma's STRO-004 Demonstrates Robust Antitumor Activity Across TF-Expressing Solid Tumor PDX Models With Improved Efficacy Versus Benchmark ADCs At AACR 2026

Benzinga·04/20/2026 08:19:35
Listen to the news
  • STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid tumor PDX models, with improved efficacy versus benchmark ADCs
  • STRO-006 and STRO-227 show meaningful, dose-dependent antitumor activity across solid tumor models
  • Presentation of TROP2-targeted immunostimulatory ADC program partnered with Astellas highlights the potential of Sutro's platform for developing dual-payload ADCs